login
Home / Papers / BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

2751 Citations2021
Noa Dagan, Noam Barda, Eldad Kepten

This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19–related outcomes, a finding consistent with that of the randomized trial.

Abstract

This study in a nationwide mass vaccination setting suggests that the BNT162b2 mRNA vaccine is effective for a wide range of Covid-19-related outcomes, a finding consistent with that of the randomized trial.